Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17570449 | 0.90 | ALDH1A1 (0.52) | CYP19A1ALDH1A1TSHRHTTKMT2A | |
| SCHEMBL12923088 | 0.88 | CYP19A1 (0.49) | CYP19A1ALDH1A1TSHRHTTKMT2A | |
| SCHEMBL15216228 | 0.88 | CYP19A1 (0.44) | CYP19A1ALDH1A1TSHRHTTKMT2A | |
| SCHEMBL22455882 | 0.87 | CYP19A1 (0.50) | CYP19A1ALDH1A1KMT2ASMN1; SMN2FOLH1 | |
| SCHEMBL22931733 | 0.86 | ALDH1A1 (0.44) | CYP19A1ALDH1A1TSHRHTTKMT2A | |
| SCHEMBL23675903 | 0.85 | TSHR (0.53) | ALDH1A1TSHRHTTKMT2ATDP1 | |
| SCHEMBL13964301 | 0.85 | TSHR (0.53) | ALDH1A1TSHRHTTKMT2ATDP1 | |
| SCHEMBL12107697 | 0.84 | CYP19A1 (0.46) | CYP19A1ALDH1A1TSHRHTTKMT2A | |
| SCHEMBL22388963 | 0.83 | FOLH1 (0.40) | CYP19A1ALDH1A1TSHRHTTKMT2A | |
| SCHEMBL19749328 | 0.83 | HTT (0.40) | CYP19A1ALDH1A1TSHRHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9841426-B2 | Intracellular organelle peptide targeted enzyme substrates | MARKER GENE TECHNOLOGIES, INC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20120046461-A1 | STEROIDAL ANTI-HORMONE HYBRIDS | NORTHEASTERN UNIVERSITY (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046461-A1 | STEROIDAL ANTI-HORMONE HYBRIDS | ESRRA, ESRRB, NR5A1 | CYP19A1 25/4885ALDH1A1 2752/4885TSHR 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.